Abstract:3100 Background: Neurotrophic tyrosine receptor kinase ( NTRK ) gene fusions are oncogenic drivers in multiple tumors. Larotrectinib is a highly selective, central nervous system (CNS)-active tropomyosin receptor kinase (TRK) inhibitor, approved to treat adult and pediatric patients (pts) with TRK fusion cancer. In an integrated analysis of 206 pts with non-primary CNS TRK fusion cancer, larotrectinib demonstrated an investigator-assessed objective response rate (ORR) of 75%; median progression-free survival (PFS) was 35.4 months (mo; Hong et al, ASCO 2021). We report updated efficacy and safety data based on central review assessments in an expanded dataset. Methods: Data were pooled from three clinical trials (NCT02576431, NCT02122913, and NCT02637687) of pts with non-primary CNS TRK fusion cancer treated with larotrectinib. Larotrectinib was administered until disease progression, withdrawal, or unacceptable toxicity. ORR was assessed by independent review committee (IRC) per RECIST v1.1. Data cut-off was July 20, 2021. Results: As of data cut-off, 244 of 269 larotrectinib-treated pts were evaluable for efficacy by IRC. There were 25 different tumor types. The most common were soft tissue sarcoma (STS [43%], including infantile fibrosarcoma [18%] and other STS [25%]), thyroid (11%), lung (10%), salivary gland (9%), and colorectal (7% [colon, n = 18; rectal, n = 1]). Ninety-four (35%) pts were aged < 18 years; 175 (65%) were ≥18 years. Pts had gene fusions involving NTRK1 (46%), NTRK2 (3%), or NTRK3 (51%). A total of 27%, 28%, and 45% of pts had 0, 1, and ≥2 prior lines of systemic therapy, respectively. The ORR was 69% (95% confidence interval [CI] 63–75): 64 (26%) complete response (CR), including 13 (5%) pathological CR, 104 (43%) partial response , 41 (17%) stable disease, 20 (8%) progressive disease, and 15 (6%) not determined. Median time to response was 1.8 mo (range 0.9–16.2). Median duration of response (DoR) was 32.9 mo (95% CI 27.3–41.7); median follow-up was 28.3 mo. Median PFS was 29.4 mo (95% CI 19.3–34.3); median follow-up was 29.3 mo. At a median follow-up of 32.2 mo, median overall survival (OS) was not reached; the 48-mo OS rate was 64% (95% CI 55–73). Treatment duration ranged from 0.1 to 67.9 months. Treatment-related adverse events (TRAEs) were mainly Grade 1–2; 50 (20%) pts had Grade 3–4 TRAEs. Five (2%) pts discontinued treatment due to TRAEs. To exclude the possible confounding effect of ongoing enrollment on median DoR, we conducted an exploratory analysis in the subset of 164 pts who were analyzed as of July 2019. The ORR was 74% (95% CI 67–81) and median DoR was 34.5 mo (95% CI 27.6–43.3); median follow-up was 34.1 mo. Conclusions: With longer follow-up, larotrectinib continued to demonstrate rapid and durable responses, extended survival benefit, and a favorable safety profile. These results highlight the importance of testing for NTRK gene fusions in cancer pts. Clinical trial information: NCT02576431, NCT02122913, NCT02637687.

Zurletrectinib is a next-generation TRK inhibitor with strong intracranial activity against NTRK fusion-positive tumours with on-target resistance to first-generation agents

Tissue-Agnostic Targeting of Neurotrophic Tyrosine Receptor Kinase Fusions: Current Approvals and Future Directions

Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion‐driven non‐small cell lung cancer

TRK inhibitor activity and resistance in TRK fusion-positive cancers in adults

Ctni-07. Long-Term Efficacy And Safety Of Larotrectinib In Patients With Trk Fusion Primary Central Nervous System (Cns) Tumors: An Updated Analysis

Long-term Efficacy and Safety of Larotrectinib in Patients with TRK Fusion Lung Cancer.

Efficacy and safety of larotrectinib in TRK fusion-positive primary central nervous system tumors

Larotrectinib long-term efficacy and safety in adult patients (pts) with tropomyosin receptor kinase (TRK) fusion cancer.

NTRK fusions in lung cancer: From biology to therapy

Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.

Safety, Pharmacokinetics (PK), and Clinical Efficacy of ICP-723, a Highly Selective Next-Generation Pan-Trk Inhibitor, in Patients with Solid Tumor.

Discovery of novel indazole derivatives as second-generation TRK inhibitors

Resistance to TRK inhibition mediated by convergent MAPK pathway activation

Targeting RET-rearranged non-small-cell lung cancer: future prospects

Discovery of 3-pyrazolyl-substituted pyrazolo[1,5-a]pyrimidine derivatives as potent TRK inhibitors to overcome clinically acquired resistance

Abstract LB389: Highly potent and selective RET inhibitor with robust anti-tumor activities against wild-type and acquired drug-resistant mutations

Efficacy and Safety of Larotrectinib in Patients with Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers.

Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.

Abstract LB388: Super potent and efficacious ALK/ROS1/TRK inhibitor that overcomes multiple drug-resistant mutations

Long-term efficacy and safety of larotrectinib in patients with tropomyosin receptor kinase (TRK) fusion lung cancer.

Discovery of 1-{(3R,4R)-3-[5-Chloro-2-(1-methyl-1H-pyrazol-4-ylamino)-7H-pyrrolo[2,3-d]pyrimidin-4-yloxymethyl]-4-methoxy-pyrrolidin-1-yl}propenone (PF-06459988), A Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants.